TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07467239: A Prospective, Participant- and Evaluator-blinded, Randomized, Controlled, Split-face Clinical Investigation to Evaluate the Performance and Safety of Polycaprolactone 300 (DMFI300) for the Treatment of Nasolabial Folds

Sponsor: Samyang Biopharmaceuticals Corporation · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 30 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$8,466,000

Rescue Site Savings

+$5,577,600

Unlock Full NCT07467239 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07467239 Rescue Dossier →